2 episodes of afternoon agitation resolved with redirection and a walk, no PRN psychotropic; antipsychotic remains at the reduced dose with the target symptom stable. Supports Section E, F758 non-pharm-first, and the GDR goal.
Successful GDR step
Antipsychotic reduced 25% per the GDR schedule with the target symptom remaining stable over two weeks — RN monitoring confirms tolerance; supports Section N and the GDR goal; next reduction dated.
Antidepressant meeting indication
Mood improved, PHQ down, appetite/sleep improved, no adverse effects — medication meeting its documented indication with no unnecessary-drug concern; supports Section D/N.
